Genetic polymorphism of CYP17 and breast cancer risk in Korean women

Shin, Minho; Lee, Kyoung Mu; Yang, Jung Hyun; Nam, Seok Jin; Kim, Jong Won; Yoo, Keun-Young; Park, Sue Kyung; Noh, Dong‐Young; Kim, Bongcheol; Kang, Daehee

doi:10.1038/emm.2005.2

Cited by 24 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The polymorphisms were detected using a modified PCR-RFLP method [14,15]. The PCR primers were synthesized by TAG Copenhagen A/S.…”

Section: Genotypingmentioning

confidence: 99%

Role of polymorphism of methyltetrahydrofolate-homocysteine methyltransferase (MTR) A2756G and breast cancer risk

Hosseini¹

2013

pjp

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common causes of death among women, and second in Iran. The objectives of this study were to determine the frequency of methyltetrahydrofolate-homocysteine methyltransferase (MTR) 2756 gene polymorphism in patients with breast cancer. For the first time, we evaluated these polymorphisms and effects on the breast cancer risk association in an Iranian sporadic populationbased case-control study of 282 breast cancer cases and 310 controls using a PCR-RFLP-based assay. Analyses of affected and controls show that homozygote genotype MTR 2756 AA has the highest frequency in both groups (33.3 in patients). Genotype MTR 2756 GG was the highest risk factor in our population [AG/GG odds ratio, 0.329 (95% CI: 0.146-0.741) p = 0.006, AA/AG, OR, 2.316, 95% CI: 1.509-3.555, p = 0.001, AA/GG odds ratio, 0.761 (95% CI: 0.363-1.595) p = 0.297]. There was a significant association of breast cancer risk with MTR 2756 GG and AA polymorphism.

show abstract

“…The polymorphisms were detected using a modified PCR-RFLP method [14,15]. The PCR primers were synthesized by TAG Copenhagen A/S.…”

Section: Genotypingmentioning

confidence: 99%

Role of polymorphism of methyltetrahydrofolate-homocysteine methyltransferase (MTR) A2756G and breast cancer risk

Hosseini¹

2013

pjp

View full text Add to dashboard Cite

show abstract

“…Three previous systematic reviews (in 1999 [33] and in 2002 [34,35]) concluded that risk was not significantly or weakly associated with CYP17 T34C polymorphism. Nevertheless, more recent case-control studies showed that an increased occurrence of breast cancer in carriers of C allele [24,25,27,29,32].…”

Section: Introductionmentioning

confidence: 96%

Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis

Chen

Pei²

2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

A number of studies have been investigated the association between CYP17 T34C polymorphism and the risk of breast cancer; the results of these studies are inconsistent, however. This fact implies that the effect of CYP17 T34C polymorphism on susceptibility to breast cancer may be modified by other risk factors. In order to provide a more definitive conclusion, a full meta-analysis combining and summarizing 24 studies was first performed. Both traditional method and Bayesian approach were applied. Odds ratio was estimated using a dominant mode of inheritance after a biological justification for the choice of genetic model. The results of homogeneity analysis (H = 1.16, I (2) = 25.4%, and P = 0.127) suggested the presence of heterogeneity across the studies. Thus, random effects models simulated by the DerSimonian-Laird method were employed. The capability of a Bayesian approach was highlighted in the estimation of a pooled odds ratio and 95% confidence interval. The results of meta-analysis (OR = 1.001, CI = 0.832-1.208) suggest no significant association in the combined populations. Furthermore, Bayesian meta-regression and subgroup analysis were conducted to investigate the sources of heterogeneity. The risk factors evaluated in the study were menopausal status, ethnicity, age at menarche, age at first birth, parity, use of oral contraceptives, body mass index (BMI), and use of hormone repair therapy (HRT). After these population stratifications, there was evidence indicating that a possible impact of menopausal status, age at menarche, and BMI on the association between CYP17 T34C polymorphism and the risk of breast cancer.

show abstract

“…Due to individual differences in exposure to factors modifying genetic levels of E 2 , however, a relationship between CYP17 genetic polymorphism and risk of breast cancer may not be detectable. Several studies tested the relationship between CYP17 polymorphism and risk of breast cancer (23,37,42,(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59), but results are conflicting.…”

Section: Discussionmentioning

confidence: 99%

CYP17Genotypes Differ in Salivary 17-β Estradiol Levels: A Study Based on Hormonal Profiles from Entire Menstrual Cycles

Jasieńska¹,

Kapiszewska

Ellison

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Variation in the levels of sex-steroid hormones results from differences in developmental conditions, adult lifestyle, and genetic polymorphism. Genes involved in sex-steroid biosynthesis have been implicated to influence levels of hormones in premenopausal women, but the results were inconclusive. We tested variation among women in levels of salivary estradiol (E 2 ) corresponding to CYP17 genotypes. CYP17 encodes cytochrome P450c17A, which mediates two enzymes important in E 2 synthesis. In contrast to the earlier studies that relied on one or a few samples for assessing the E 2 levels of an individual woman, our study is based on daily collected saliva samples for one entire menstrual cycle. Sixty Polish women, ages 24 to 36 years, with regular menstrual cycles and no reported fertility problems participated in the study. Women with A2/A2 genotype had 54% higher mean E 2 levels than women with A1/A1 genotype (P = 0.0001) and 37% higher than women with A1/A2 genotype (P = 0.0008). Heterozygous A1/A2 women had 13 % higher E 2 levels than homozygous A1/A1 women (but this difference was significant only in a nonparametric test). Levels of E 2 during the day with highest E 2 (day À1) were 72% higher in A2/A2 compared with A1/A1 (P = 0.01) and 52 % higher compared with A1/A2 (P = 0.03). Our results suggest that CYP17 genotype may serve as a biomarker of endocrine function in women of reproductive age. (Cancer Epidemiol Biomarkers Prev 2006;15(11):2131 -5)

show abstract

Genetic polymorphism of CYP17 and breast cancer risk in Korean women

Abstract: A bstractC

Cited by 24 publications

References 15 publications

Role of polymorphism of methyltetrahydrofolate-homocysteine methyltransferase (MTR) A2756G and breast cancer risk

Role of polymorphism of methyltetrahydrofolate-homocysteine methyltransferase (MTR) A2756G and breast cancer risk

Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis

CYP17Genotypes Differ in Salivary 17-β Estradiol Levels: A Study Based on Hormonal Profiles from Entire Menstrual Cycles

Contact Info

Product

Resources

About